In Alzheimer’s disease (AD), GRN cerebrospinal fluid (CSF) levels rise with disease progression and correlate with cognitive impairment and with the expression of the microglia derived soluble TREM2 (triggering receptor expressed on myeloid cells 2) (Suárez-Calvet et al., 2018). The gene discussed is TREM2; the disease is Alzheimer disease.